TALENTACE: TACE combined with atezolizumab + bevacizumab in uHCC

32 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Lorenza Rimassa, MD, Hunimed University, Milan, Italy, discusses TALENTACE (NCT047126430), a positive Phase III Asian trial combining atezolizumab-bevacizumab with on-demand TACE versus TACE alone in intermediate-stage HCC. The study met its progression-free survival endpoints using both composite TACE-PFS and RECIST criteria, with higher response rates in the combination arm. While demonstrating clear benefit for high tumor burden patients, Prof. Rimassa notes important limitations, including a lack of centralized imaging review and incomplete safety data regarding treatment duration and bleeding/thrombosis risks. Overall survival data remain immature. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo